PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26679853-3 2015 Monotherapy with boosted darunavir and lopinavir has been safely prescribed as maintenance therapy to stable patients on stable antiretroviral therapy without nadir CD4 count < 200/mm3, low-level baseline viremia, prolonged viral suppression, and without prior virologic failure. Darunavir 25-34 CD4 molecule Homo sapiens 165-168 31560700-0 2019 A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naive patients with CD4<200 cells/uL (the PRADAR study). Darunavir 59-68 CD4 molecule Homo sapiens 135-138 25715484-4 2014 A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 mul) of CD4+ lymphocyte count in patients who took darunavir (362.2 in mul) and in those who used atazanavir (285.1 in mul). Darunavir 28-37 CD4 molecule Homo sapiens 157-160 25929922-1 2015 The purpose of this article is to evaluate the evolution of microbial translocation (MT) and its role in CD4 and CD8 T cells immune activation (IA) in HIV-1-infected patients on ritonavir-boosted darunavir monotherapy (mtDRV/rtv).Prospective study of consecutive HIV-1-infected patients switched to mtDRV/rtv as a simplification regimen. Darunavir 196-205 CD4 molecule Homo sapiens 105-108 24396625-14 2013 Darunavir/ritonavir-based therapy demonstrated improvements in CD4+ cell recovery and association with progressive functional immune recovery over 48 weeks. Darunavir 0-9 CD4 molecule Homo sapiens 63-66 25715484-4 2014 A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 mul) of CD4+ lymphocyte count in patients who took darunavir (362.2 in mul) and in those who used atazanavir (285.1 in mul). Darunavir 200-209 CD4 molecule Homo sapiens 157-160 22549499-0 2012 High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. Darunavir 13-22 CD4 molecule Homo sapiens 118-121 23562640-7 2013 In multivariate analysis, baseline VL and CD4 count and >= 2 new antiretrovirals among darunavir, etravirine, maraviroc and enfuvirtide were associated with VR to RAL. Darunavir 90-99 CD4 molecule Homo sapiens 42-45 22549499-3 2012 Pharmacokinetic and pharmacodynamic evaluations justified the individualized use of high-dose darunavir, which resulted in virologic suppression, improved CD4 cell count, and resolution of toxicity. Darunavir 94-103 CD4 molecule Homo sapiens 155-158 21692667-5 2011 In treatment-naive patients, boosted darunavir administered once daily was noninferior to boosted lopinavir, and showed higher virologic and immunological response rates in patients with high baseline viral load and low baseline CD4(+) cell counts. Darunavir 37-46 CD4 molecule Homo sapiens 229-232 17621459-0 2007 Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients. Darunavir 73-82 CD4 molecule Homo sapiens 55-58 21182350-0 2010 Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER. Darunavir 61-70 CD4 molecule Homo sapiens 120-123 21182350-8 2010 CONCLUSIONS: Darunavir-based HAART may lower non-antiretroviral-related costs compared with control PI-based therapy in highly treatment-experienced, HIV-infected patients during the first year of therapy by improving patients" CD4 cell counts. Darunavir 13-22 CD4 molecule Homo sapiens 228-231 19940948-10 2009 Moreover, darunavir has shown superior antiviral efficacy than lopinavir, particularly in three situations of particular clinical concern: high baseline viral load, low baseline CD4 counts, and suboptimal drug adherence. Darunavir 10-19 CD4 molecule Homo sapiens 178-181 17803366-4 2007 The effects of rising CD4 counts with darunavir/r 600/100 mg twice daily on healthcare costs were predicted by using the US cohort data and published US antiretroviral drug prices. Darunavir 38-47 CD4 molecule Homo sapiens 22-25 17461851-0 2007 Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. Darunavir 53-59 CD4 molecule Homo sapiens 86-89 17461851-6 2007 RESULTS: The CD4 categorization method predicted a 48% reduction in clinical progression to AIDS/death for TMC114/r vs. CPI. Darunavir 107-113 CD4 molecule Homo sapiens 13-16 17621459-7 2007 Cost per 25 cell rise in CD4 ranged from $132 for darunavir/r to $16,464 for T-20. Darunavir 50-59 CD4 molecule Homo sapiens 25-28